Novel effects with polyethylene glycol modified pharmaceuticals.
about
A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment.Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers.Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.Hydrogel-electrospun fiber mat composite coatings for neural prostheses.Modelling chemotherapy effects on granulopoiesis.'Click' synthesis of dextran macrostructures for combinatorial-designed self-assembled nanoparticles encapsulating diverse anticancer therapeuticsLong-circulating polymeric nanovectors for tumor-selective gene delivery.Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy.The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literature.MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients.Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects.PEG Quantitation Using Reversed-Phase High-Performance Liquid Chromatography and Charged Aerosol Detection.Quantitative analysis of PEG-functionalized colloidal gold nanoparticles using charged aerosol detection.
P2860
Q33712928-5E1C4B88-CBBB-4FB2-ACB6-F25213198F69Q33858681-AD0E58A3-71DD-4D00-B7C2-E4E56FF3862BQ34473329-340EA158-4C93-47EC-A48C-9C2C3AD336D0Q34701296-15060823-6DF8-4DE5-98D3-EBD6618C3C4DQ34996295-B826387F-4F2E-4704-B901-300BB0AAB90FQ35380806-A8E48172-92F3-45C6-91B0-77B611946398Q36314788-0141023D-1EA7-4561-A715-E138BBB36E79Q36677460-6CCF1CBD-50C7-41C4-9308-08B3B092B6C3Q37668347-5C54472B-3931-4A37-8785-16543E0A4134Q38068463-686DBE59-D29A-4B77-8210-1E67979F127AQ40016483-131F84E8-DB55-47A0-A90D-795D318276D4Q40369205-E32F045A-0392-4053-B9B2-EAE355ACA3ACQ44019603-CD885760-0917-479B-9249-1EB47325C286Q50078004-4C76F951-2EDF-47ED-80E2-9A05D21B6151Q53591003-16DDA9FF-8413-4BB9-ADC7-8566E2E91D03
P2860
Novel effects with polyethylene glycol modified pharmaceuticals.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Novel effects with polyethylene glycol modified pharmaceuticals.
@ast
Novel effects with polyethylene glycol modified pharmaceuticals.
@en
Novel effects with polyethylene glycol modified pharmaceuticals.
@nl
type
label
Novel effects with polyethylene glycol modified pharmaceuticals.
@ast
Novel effects with polyethylene glycol modified pharmaceuticals.
@en
Novel effects with polyethylene glycol modified pharmaceuticals.
@nl
prefLabel
Novel effects with polyethylene glycol modified pharmaceuticals.
@ast
Novel effects with polyethylene glycol modified pharmaceuticals.
@en
Novel effects with polyethylene glycol modified pharmaceuticals.
@nl
P1476
Novel effects with polyethylene glycol modified pharmaceuticals.
@en
P2093
Blackwell S
P356
10.1016/S0305-7372(02)80002-0
P478
28 Suppl A
P577
2002-04-01T00:00:00Z